Ongoing Clinical Trials (Not Recruiting)
Access our list of ongoing clinical trials (Not Recruiting)
Lung Cancer
Daiichi Sankyo DS1062-A-U303
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Study LinkDaiichi Sankyo DS1062-A-U304
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
Study LinkMCLA-158-CL04
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment
Study LinkSolid Tumour
Revolution Medicines RMC-6291-001
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Study LinkSeagen SGNDV-005
Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors that Express HER2
Study LinkAscendis ASND0029
TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies
Study LinkSeagen SGNDV-004
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Study LinkOncozen OZS001-101
A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumors with a Focus on Triple Negative Breast Cancer
ANZCTR ACTRN12625000163404Prostate Cancer
USyd ENZAMET
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Study LinkBreast Cancer
Daiichi Sankyo DS8201-A-U302
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan) Versus Ado Trastuzumab Emtansine for HER2-Positive, Unresectable and/or Metastatic Breast Cancer
Study LinkHaematological Malignancies
Regeneron R1979-ONC-1625
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study LinkAscentage APG-2575CU101
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (SACRED)
Study LinkBladder and Urothelial Cancer
Seagen RC48-G001
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Subjects with HER2-Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Study LinkRactigen RAG-01-01
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients with Non-muscle-invasive Bladder Cancer Who Have Failed Bacillus Calmette-Guérin Therapy
Study Link